What can be expected from the Indian Pharmaceutical market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.
Our 194-page report provides 117 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole of the Indian pharmaceutical market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2016-2026 and other analyses show you commercial prospects Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.
See revenue forecasts for the leading submarkets and indications How will submarkets perform to 2026? Our study forecasts revenues in the following Indian Pharmaceutical submarkets: • Generic Drugs • Over-The-Counter (OTC) Drugs • Patented Drugs • Biosimilars
See revenue forecasts for the leading therapeutic areas How will leading therapeutic areas perform to 2026? Our study forecasts revenues in therapeutic areas including: • Infectious disease drugs • Cardiovascular disease drugs • Gastro-intestinal drugs • Respiratory disease • Pain relief / analgesics • Diabetes • Vitamins / Minerals / Nutrients • Dermatology • Central Nervous System (CNS) • Gynaecology
Leading companies and potential for market growth Overall revenue for the Indian Pharmaceutical market will reach $36.18bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. An ageing population, increasing access to healthcare and increasing incidence of chronic diseases, especially diabetes and cardiovascular disease, will drive sales to 2026.
Our work analyses the key companies in the market. See Visiongain’s analysis of leading companies, including these: • Sun Pharmaceutical Industries Limited • Abbott Healthcare Private Limited (Abbott India) • Cipla Ltd. • Cadila Healthcare Ltd. • GlaxoSmithKline Pharmaceuticals Limited (GSK India) • Pfizer Limited. India • Lupin Pharmaceuticals, Inc.,
A company profile gives you the following information where available: • Discussion of a company’s activities and outlook • Historic revenue, analysis and discussion of company performance over the past 10 years • Analysis of major products currently on the market • Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect Indian pharmaceutical industry? Our new report discusses issues and events affecting the Indian pharmaceutical market. You will find discussions, including qualitative analyses: • Highly diverse market needing strong knowledge of key therapeutic indications • Changing regulatory landscape challenging new entrants and major market players alike • Emerging drug types with the potential to reshape the market
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Indian Pharmaceutical Market Forecast 2015-2026 report helps you In summary, our 194-page report gives you the following knowledge: • Revenue forecasts to 2026 for the Indian Pharmaceutical market – discover the industry’s prospects, finding promising places for investments and revenues • Revenue forecasts to 2026 for each major submarket – discover prospects for leading pharmaceutical products in the following areas: Infectious disease drugs, Cardiovascular disease drugs, Gastro-intestinal drugs, Respiratory disease , Pain relief / analgesics, Diabetes, Vitamins / Minerals / Nutrients, Dermatology, Central Nervous System (CNS), Gynaecology • Revenue forecasts to 2026 for the leading drug types – generics, OTC products, patented drugs and biosimilars • Assessment of leading companies – analysis of products, revenue, mergers & acquisitions, sales by region, therapeutic area and product type • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the indian pharmaceutical market and leading companies. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 The Indian Pharmaceutical Market Overview 1.2 Indian Pharmaceutical Market Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Key Questions Answered by This Analytical Report 1.6 Who is This Report For? 1.7 Methodology 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Reports 1.10 About Visiongain
2. Indian Healthcare: Overview 2.1 India: Demographic Indicators Overview 2.2 Indian Healthcare system: Overview 2.2.1 Rashtriya Swasthya Bima Yojana – Bringing Healthcare Coverage to India’s Poorest Workers 2.3 Analysis of India’s Healthcare Expenditure 2.4 State Bodies regulating the Indian Pharmaceutical Market 2.4.1 The Drugs and Cosmetics Act, 1940
3. Indian Pharmaceutical Market: Discussions and Predictions 2016-2026 3.1 Indian Pharmaceutical Market: The Third Biggest Market in the World by Volume, 2015 3.2 Indian Pharmaceutical Market: Overall Revenue Forecast 2016-2026
4. Medical Treatment Needs in India, 2016-2026 4.1 Disease Prevalence in India, 2016-2026 4.2 Disease Incidence in India, 2016-2026 4.3 Disease Mortality Rates in India, 2016-2026 4.3.1 Top Causes of Death in India 4.3.2 Top Causes of Death in India: Mortality Projections, 2016-2026
5. Indian Pharmaceutical Market: Leading Therapeutic Areas, 2016-2026 5.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Overview, 2015 5.2 Indian Pharmaceutical Market: Leading Therapeutic Areas Forecasts, 2016-2026 5.3 Infectious Disease Therapeutics: Overview, 2015 5.3.1 Infectious Disease Drugs Market: Forecast, 2016-2026 5.3.2 Diarrheal Diseases Responsible for Over Half a Million Annual Deaths, 2015 5.3.3 Lower Respiratory Tract Infections Among Leading Causes of Death in 2015 5.3.4 Tuberculosis Still Rife in India 5.3.5 Malaria, Risk and Opportunity 5.3.6 HIV in India: Growing Therapeutic Area Worth Watching 5.3.7 Drivers and Restraints for the Infectious Diseases Pharmaceutical Segment, 2015-2026 5.4 Cardiovascular Therapeutic Segment: Overview, 2015 5.4.1 Cardiovascular Disease – India’s Leading Cause of Death, 2015 5.4.2 Cardiovascular Drugs Market: Forecast, 2016-2026 5.4.3 Drivers and Restraints for the Indian Cardiovascular Drugs Market, 2015-2026 5.5 Gastro-Intestinal Therapeutic Segment: Overview, 2015 5.5.1 Gastro-Intestinal Drugs Market: Forecast, 2016-2026 5.5.2 Gastro-Intestinal Drugs in India: Challenges and Opportunities 5.5.3 Drivers and Restraints for the Gastro-Intestinal Drugs Segment, 2015 5.6 Respiratory Therapeutic Segment: Overview, 2015 5.6.1 Respiratory Disease Drugs Market: Forecast, 2016-2026 5.6.2 Drivers and Restraints for the Respiratory Diseases Segment, 2015 5.7 Pain Relief / Analgesics Therapeutic Segment: Overview, 2015 5.7.1 Pain Relief / Analgesics Drugs Market: Forecast, 2016-2026 5.7.2Drivers and Restraints for the Pain Relief / Analgesics Drugs Segment, 2015 5.8 Diabetes Therapeutic Segment: Overview, 2015 5.8.1 Diabetes Drugs Market: Forecast, 2016-2026 5.8.2 Drivers and Restraints for the Diabetes Drugs Segment, 2015 5.9 Vitamins / Minerals / Nutrients Therapeutic Segment: Overview, 2015 5.9.1 Vitamins / Minerals / Nutrients Drugs Market: Forecast, 2016-2026 5.9.2 Vitamins / Minerals / Nutrients in India: Challenges and Opportunities 5.9.3 Drivers and Restraints for the Vitamins / Minerals / Nutrients Drugs Segment, 2015 5.10 Dermatological Therapeutic Segment: Overview, 2015 5.10.1 Dermatological Drugs Market: Forecast, 2016-2026 5.10.2 Drivers and Restraints for the Dermatological Drugs Segment, 2015 5.11 Central Nervous System (CNS) Therapeutics: Overview, 2015 5.11.1 CNS Drugs Market: Forecast, 2016-2026 5.11.2 Intentional Injury Among the Top 10 Leadireasing Investment in the Healthcare System 8.3.2 The Disease Burden and GDP Both Growing 8.3.3 India’s Population Set to Become the World’s Largest by 2030 8.3.4 India Popular for Pharmaceutical Outsourcing 8.4 Weaknesses 8.4.1 Stringent Pricing Regulations Hit the Indian Pharmaceutical Market 8.4.2 Poor Infrastructure Threatens to Hinder Market Potential 8.4.3 Intense Competition Driving Down Drug Prices 8.5 Opportunities 8.5.1 Global Demand for Generics Rising 8.5.2 National Rural Health Mission Driving Healthcare Access in Rural Areas 8.5.3 Significant Investment from MNCs Expected 8.5.4 Innovative Biotechnology Sector Set to Capitalise on Patent Expiries 8.6 Threats 8.6.1 Rise of Other Low-Cost Generic Exporters 8.6.2 Will the Indian Government Stick to Increasing Healthcare Expenditure? 8.6.3 Recent Warnings and Export Bans from Regulatory Bodies Hit Confidence in Indian Pharmaceuticals 8.7 Porter’s Five Forces Analysis of the Indian Pharmaceutical Market 8.7.1 Rivalry Among Competitors [High] 8.7.2 Threat of New Entrants [Low] 8.7.3 Power of Suppliers [Medium] 8.7.4 Power of Buyers [High] 8.7.5 Threat of Substitutes [Low]
9. Conclusion 9.1 The Indian Pharmaceutical Market: Growing Global Market Share 9.2 Indian Pharmaceutical Market: Chronic Diseases Becoming Increasingly Prevalent 9.3 Commercial Drivers of the Indian Pharmaceutical Market 9.4 Commercial Restraints of the Indian Pharmaceutical Market 9.5 Concluding Remarks
10. Glossary Associated Visiongain Reports Visiongain Report Sales Order Form Appendix A About Visiongain Appendix B Visiongain report evaluation form
List of Tables Table 1.1 Rupee to Dollar Historical Exchange Rates 2006-2015 Table 1.2 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%) by Therapeutic Area, 2015-2026 Table 3.1 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 4.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014 Table 4.2 Leading Types of Cancer in India by Age-Standardised Death Rate (per 100,000 People), 2014 Table 4.3 Causes of Death in India by World Ranking, 2014 Table 5.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2015, 2020, 2026 Table 5.2 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%) by Therapeutic Area, 2015-2026 Table 5.3 The Infectious Disease Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.4 The Indian Cardiovascular Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.5 The Indian Gastro-Intestinal Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.6 The Indian Respiratory Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.7 The Indian Pain Relief / Analgesics Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.8 The Indian Diabetes Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.9 The Indian Vitamins / Minerals / Nutrients Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.10 The Indian Dermatological Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.11 The Indian CNS Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.12 The Indian Gynaecological Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 5.13 The Indian Other Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 6.1 Leading Drug Types in the Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2015, 2020 and 2026 Table 6.2 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%), CAGR (%) by Drug Type, 2015-2026 Table 6.3 The Indian Generic Drug Market: Revenue ($bn), AGR (%) and CAGR (%) 2015-2026 Table 6.4 The Indian OTC Drug Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 6.5 The Indian Patented Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 6.6 Selected Biosimilar Therapeutics on the Indian Market, 2015 Table 6.7 Selected Biosimilar Therapeutics on the Indian Market, 2015 (continued) Table 6.8 The Indian Biosimilar Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026 Table 6.9 Selected Blockbuster Biologic Patent Expiries in the US and EU, 2015-2028 Table 6.10 Selected Late-Stage Biosimilar Pipeline Products, 2015 Table 7.1 Top 50 Companies in the Indian Pharmaceutical Market: Revenue (Rs.m), Revenue ($m) and Market Share (%), 2015 Table 7.2 Sun Pharmaceuticals: Revenue Share (%) by Business Area, 2006, 2010 and 2015 Table 7.3 Sun Pharmaceuticals: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Business Area, 2015 Table 7.4 Sun Pharmaceuticals: Revenue (Rs.m), Revenue ($m), AGR (%) and CAGR (%), 2006-2015 Table 7.5 Sun Pharmaceuticals: M&A Activity, 1997-2015 Table 7.6 Abbott India: Market Share (%) and Market Rank of Key Brands Table 7.7 Abbott India: Revenue (Rs.m), Revenue ($m), AGR (%) and CAGR (%), 2006-2015 Table 7.8 Abbott India: Key Products in India, Market Share (%) and Rank, 2015 Table 7.9 Abbott India: Key Products in India, Market Share (%) and Rank, 2015 (continued) Table 7.10 Cipla: Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2006-2015 Table 7.11 Cipla: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Geographical Area, 2015 Table 7.12 Cadila Healthcare Ltd.: Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2006-2015 Table 7.13 Cadila Healthcare Ltd.: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Therapeutic Area, 2015 Table 7.14 Cadila Healthcare Ltd.: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Business Area, 2015 Table 7.15 GlaxoSmithKline India: Key Products in the Indian Market, 2015 Table 7.16 GlaxoSmithKline India: Key Products in the Indian Market, 2015 (continued) Table 7.17 GlaxoSmithKline India Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2006-2015 Table 7.18 GlaxoSmithKline India: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Product Type, 2015 Table 7.19 Pfizer India: Leading Brands on the Indian Market 2015 Table 7.20 Pfizer India: Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2006-2015 Table 7.21 Pfizer India: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Product Type, 2015 Table 7.22 Lupin: Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2006-2015 Table 7.23 Lupin: Revenue Share (%) by Therapeutic Area, 2015 Table 7.24 Growth of Top Brands (%), by Therapeutic Area, 2015 Table 8.1 SWOT Analysis of the Indian Pharmaceutical Market, 2015-2026
List of Figures Figure 1.1 Indian Pharmaceutical Market: Overview of Submarkets Figure 2.1 Indian Population: Rural and Urban Populations (bn) and Percent of Population in Urban Areas (%), 1980-2015 Figure 2.2 Indian Population: Total Population (bn) and Annual Population Growth Rate (%), 2006-2014 Figure 2.3 Indian GDP ($bn) and GDP growth (%), 2006-2014 Figure 2.4 Access to Improved Water Sources as a Proportion of Total Population (%) and Access to Improved Sanitation as a Proportion of Total Population (%), 2006-2015 Figure 2.5 Indian GDP ($bn) and Health Expenditure as a Proportion of GDP (%), 2006-2013 Figure 2.6 Health Expenditure: Public Health expenditure as a Proportion of Total Health Expenditure (%) and Out of Pocket Expenditure as a Proportion of Private Health Expenditure 2006-2013 Figure 3.1 The Indian Pharmaceutical Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 4.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014 Figure 5.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2015 Figure 5.2 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2020 Figure 5.3 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2026 Figure 5.4 The Infectious Disease Drugs Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.5 Malaria cases (m), P. falciparum cases (m) and Proportion of P. falciparum cases (%) in India, 1995-2014 Figure 5.6 Infectious Disease Market in India: Drivers and Restraints, 2015-2026 Figure 5.7 The Indian Cardiovascular Drugs Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.8 Cardiovascular Drugs Market in India: Drivers and Restraints, 2015-2026 Figure 5.9 The Indian Gastro-Intestinal Drugs Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.10 Gastro-intestinal Drugs Market in India: Drivers and Restraints, 2015-2026 Figure 5.11 The Indian Respiratory Drugs Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.12 Respiratory Drugs Market in India: Drivers and Restraints, 2015-2026 Figure 5.13 The Indian Pain Relief / Analgesics Drugs Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.14 Pain Relief / Analgesics Drugs Market in India: Drivers and Restraints, 2015-2026 Figure 5.15 The Indian Diabetes Drugs Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.16 Diabetes Drugs Market in India: Drivers and Restraints, 2015-2026 Figure 5.17 The Indian Vitamins / Minerals / Nutrients Drugs Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.18 Vitamins / Minerals / Nutrients Market in India: Drivers and Restraints, 2015-2026 Figure 5.19 The Indian Dermatological Drugs Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.20 Dermatological Drugs Market in India: Drivers and Restraints, 2015-2026 Figure 5.21 The Indian CNS Drugs Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.22 CNS Drugs Market in India: Drivers and Restraints, 2015-2026 Figure 5.23 The Indian Gynaecological Drugs Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 5.24 Gynaecological Drugs Market in India: Drivers and Restraints, 2015-2026 Figure 5.25 The Indian Other Drugs Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 6.1 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2015 Figure 6.2 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2020 Figure 6.3 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2026 Figure 6.4 The Indian Generic Drug Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 6.5 Generic Drug Market in India: Drivers and Restraints, 2015-2026 Figure 6.6 The Indian OTC Drug Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 6.7 OTC Drug Market in India: Drivers and Restraints, 2015-2026 Figure 6.8 The Indian Patented Drugs Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 6.9 Patented Drugs Market in India: Drivers and Restraints, 2015-2026 Figure 6.10 The Indian Biosimilar Drugs Market: Revenue ($bn) and AGR (%), 2015-2026 Figure 6.11 Biosimilar Drug Market in India: Drivers and Restraints, 2015-2026 Figure 7.1 Sun Pharmaceuticals: Revenue Share (%) by Business Area, 2006 Figure 7.2 Sun Pharmaceuticals: Revenue Share (%) by Business Area, 2010 Figure 7.3 Sun Pharmaceuticals: Revenue Share (%) by Business Area, 2015 Figure 7.4 Sun Pharmaceuticals: Revenue ($m) and AGR (%), 2006-2015 Figure 7.5 Abbott India: Revenue ($m) and AGR (%), 2006-2015 Figure 7.6 Cipla Revenue ($m) and AGR (%), 2006-2015 Figure 7.7 Cipla: Revenue Share (%) by Geographical Area, 2015 Figure 7.8 Cadila Healthcare Ltd.: Revenue ($m) and AGR (%), 2006-2015 Figure 7.9 Cadila Healthcare Ltd.: Revenue Share (%) by Business Area, 2015 Figure 7.10 Cadila Healthcare Ltd.: Revenue Share (%) by Business Area, 2015 Figure 7.11 GlaxoSmithKline India: Revenue ($m) and AGR (%), 2006-2015 Figure 7.12 GlaxoSmithKline India: Revenue Share (%) by Product Type, 2015 Figure 7.13 Pfizer India: Revenue ($m) and AGR (%), 2006-2015 Figure 7.14 Pfizer India: Revenue Share (%) by Product Type, 2015 Figure 7.15 Lupin: Revenue ($m) and AGR (%), 2006-2015 Figure 7.16 Lupin: Revenue Share (%) by Therapeutic Area, 2015 Figure 8.1 Indian Pharmaceutical Market: Drivers and Restraints, 2015-2026 Figure 8.2 Porter’s Five Forces Analysis of the Indian Pharmaceuticals Market, 2016-2026
Sun Pharmaceuticals Industries Ltd Abbott India Cipla Cadila Healthcare Ltd. Mankind Alkem GSK India Macleods Pfizer India Lupin Intas Pharma Torrent Pharma Emcure Sanofi India Aristo Pharma Dr Reddy's Labs Glenmark Pharma USV Micro Labs Alembic Novartis India Ipca Labs Wockhardt FDC Unichem MSD Pharma Cadila Pharma Merck KGaA Franco India Indoco Eris Lifesciences The Himalaya Drug Company Divis Laboratories Blue Cross Laboratories Ltd. JB Chemicals Bharat Serums AstraZeneca Meyer Organics Raptakos, Brett & Co. Ltd Akumentis Healthcare Ltd Hetero Drugs Ltd Wallace + Indi Pharma Medley Pharmaceuticals Ltd Janssen Win-Medicare Fourrts (India) Laboratories Pvt, Ltd Ajanta Pharma Ltd Biocon Ltd Apex Laboratories Pvt. Ltd Albert David Ltd Claris Lifesciences Lonza Bayer Natco Shantha Biotechnics Merieux Alliance Gennova Biopharmaceuticals Virchow Biotech Bioviz Technologies Gland Pharma Serum Institute of India Zenotech Laboratories Epirus Biopharmaceuticals Sandoz (Novartis) Novartis Caraco Pharmaceutical Laboratories Able Labs Cattern Chemical Inc. DUSA Pharmaceuticals Inc. Intrexon URL Merck Pharmalucence Taro Pharmaceutical Industries Ltd. Teva Pharmaceuticals Ltd. Daiichi Sankyo Piramal Healthcare Sanofi Cadila Pharmaceuticals Ltd. Medpro Pharmaceutica (Pty) Ltd. Megafine Pharma Novo Nodisk
Organisations Mentioned in the Report Central Drugs Standard Control Organisation (CDSCO) Competition Commission of India (CCI) Drug Technical Advisory Board (DTAB) Drug Consultative Committee (DCC) European Medicines Agency High Court of Punjab and Haryana Indian Patent Office (Japan’s) Minstry of Health, Labour and Welfare (MHLW) Medical Council of India (Indian) Ministry of Health National AIDS Control Organisation (NACO) (Australia’s) Therapeutic Goods Administration (TGA) UK Medicines & Healthcare Products Regulatory Agency (MHRA) US Federal Trade Commission (FTC) US Food and Drug Administration (FDA) UNAIDS World Bank World Health Organisation (WHO) World Trade Organisation (WTO)
Download sample pages
Complete the form below to download your free sample pages for Indian Pharmaceutical Market Forecast 2016-2026
Download sample pages
Complete the form below to download your free sample pages for Indian Pharmaceutical Market Forecast 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
The rising prevalence of oncological disorders, lung infections, rising demand for customised drugs coupled with new orphan diseases discoveries, are few of the major reasons responsible for development of pharmaceutical spray drying market.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
